

ANTARES PHARMA, INC.  
Form SC 13G  
February 14, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 13G**  
**Under the Securities Exchange Act of 1934**  
**(Amendment No. )\***

**Antares Pharma Inc**  
**(Name of Issuer)**  
**Common Stock**  
**(Title of Class of Securities)**  
**036642106**  
**(CUSIP Number)**  
**December 31, 2018**  
**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**SCHEDULE 13G**

CUSIP No. 036642106

(1) Names of reporting persons

UBS Group AG directly and on behalf of certain subsidiaries

(2) Check the appropriate box if a member of a group (see instructions)

(a)            (b)

(3) SEC use only

(4) Citizenship or place of organization

Switzerland

Number of (5) Sole voting power

shares (6) Shared voting power

beneficially

owned by 13,137,018

each (7) Sole dispositive power

reporting (8) Shared dispositive power

person

with: 13,137,018

(9) Aggregate amount beneficially owned by each reporting person

13,137,018

(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

(11) Percent of class represented by amount in Row (9)

8.34%

(12) Type of reporting person (see instructions)

BK

**SCHEDULE 13G**

**Page 3 of 4**

**Item 1(a) Name of issuer:** Antares Pharma Inc

**Item 1(b) Address of issuer's principal executive offices:**

100 PRINCETON SOUTH

SUITE 300

EWING NJ 08628

**2(a) Name of person filing:**

UBS Group AG

**2(b) Address or principal business office or, if none, residence:**

UBS Group AG

Bahnhofstrasse 45

PO Box CH-8098

**2(c) Citizenship:**

Switzerland

**2(d) Title of class of securities:**

Common Stock

**2(e) CUSIP No.:**

036642106

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

Edgar Filing: ANTARES PHARMA, INC. - Form SC 13G

- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 13,137,018.
- (b) Percent of class: 8.34%.

**SCHEDULE 13G**

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote \_\_\_\_\_.

(ii) Shared power to vote or to direct the vote 13,137,018.

(iii) Sole power to dispose or to direct the disposition of \_\_\_\_\_.

(iv) Shared power to dispose or to direct the disposition of 13,137,018.

**Item 5. Ownership of 5 Percent or Less of a Class.** *If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following .*

*Dissolution of a group requires a response to this item.*

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

N/A

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

This statement on Schedule 13G is being filed by UBS Group AG on behalf of itself and its wholly owned subsidiaries: UBS AG London Branch, UBS Securities LLC, and UBS Financial Services Inc.

**Item 8. Identification and Classification of Members of the Group.**

N/A

**Item 9. Notice of Dissolution of Group.**

N/A

**Item 10. Certifications**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the

securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under §240.14a-11.

**Signatures**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: 2/14/19

Signature: /s/ Jennifer Sator

Name: Jennifer Sator

Title: Director

Date: 2/14/19

Signature: /s/ Rollins Simmons

Name: Rollins Simmons

Title: Authorized Signatory